While we missed the opportunity to provide a comment prior to publication, PhRMA’s Assistant General Counsel John Murphy does have a response to the California Healthline article, "Challenged in Court, Killed in Legislature, Drug Take-Back Taking Root in Counties" (3/30).
Cancer will touch the lives of most Americans, but few understand its history. Cancer: The Emperor of All Maladies, a biography of the disease by award-winning filmmaker Ken Burns, takes on the challenge of explaining the impact of a disease which has been around since the beginning of time, and will strike more than 1.6 million Americans in 2015 alone.
As you learned in last week’s video, Medicare Part D helps seniors adhere to their medicines by providing access to prescription drug coverage. This helps beneficiaries live healthier lives by avoiding use of more costly medical services, which helps reduce spending in the broader health care ecosystem.
Here’s one example: according to a recent study from Johns Hopkins University and the University of Illinois, gaining prescription medicine coverage through Medicare Part D was tied to an eight percent decrease in hospital admissions for seniors.
Patients with artery plaque, congestive heart failure, chronic obstructive pulmonary disease and dehydration have especially benefited from a decrease in hospitalizations. Here are some examples of how beneficiaries are realizing the value of their Part D coverage.
New report on intellectual property, 5 things you should know about Medicare Part D, and more
Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending - The biopharmaceutical industry comes out on top as the country’s manufacturing leader in innovation and economic contributions in a new report from ndp│analytics. According to the analysis, the industry had the highest research and development (R&D) investment over the last decade, accounting for 27 percent of average annual R&D spending from 2000-2012.
When it comes to patient health and well-being, today’s treatment advancements are borne from and stand on the shoulders of investment in prior research and development (R&D).
As science continues to evolve, our industry is always imagining new discovery frontiers. So, this week, we discussed a few ways we’re focused on what’s next for patients.
Since 1991, cancer survival rates have increased as death rates have fallen 20 percent. On Wednesday, we introduced a new Catalyst series that explores what continued research could mean for the future for cancer patients.
“Whether it’s our family, our friends, all of us are potentially patients one day.”
In a single sentence, Dr. Anthony Coyle, senior vice president and chief scientific officer at Pfizer’s Centers for Therapeutic Innovation (CTI), sums up what inspires the researchers and scientists fueling progress at America’s biopharmaceutical companies.
Ask About Adherence is a blog series featuring Q&A’s with experts on medication adherence. In this post, we speak with Joel White, Prescriptions for a Healthy America president, on the landscape of potential solutions to non-adherence.
Today’s events at the White House and U.S. Department of Health and Human Services (HHS) highlighted the growing interest from policy makers and stakeholders in shifting the health care payment system to support greater quality of care rather than the quantity of care provided to patients. PhRMA has long supported policies to advance affordable, high-quality, individualized care, and we were pleased to participate in today’s inaugural meeting of the Learning and Action Network (LAN), an initiative of HHS to discuss payment and delivery reform.
We are at a pivotal juncture in cancer care. As highlighted in recent stories from outlets such as The New York Times, NPR and TIME, advances in science and technology (such as genomics and health information technology) are opening up new opportunities for effectively treating cancer. Continuing advances in prevention, detection, and treatment are driving up cancer survival rates and enabling people to live longer and healthier lives. At the same time, we’re in the midst of an important debate about the affordability and cost of cancer care, as well as significant changes in how we pay for and deliver care to cancer patients.
Today, PhRMA CEO John J. Castellani sent the following statement for the record to the Energy and Commerce Health Subcommittee on the hearing they’re holding on the 340B program: